Liên Minh Châu Âu - Tiếng Iceland - EMA (European Medicines Agency)

ceva santé animale - spironolactone - Þvagræsilyf - hundar - til notkunar í samsettri meðferð með hefðbundinni meðferð (þ.mt þvagræsilyfsstyrkur, ef þörf krefur) til meðferðar við hjartabilun vegna vöðvasöfnun í hundum.

Iceland - Tiếng Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

orion corporation - spironolactonum inn - tafla - 100 mg

Iceland - Tiếng Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

orion corporation - spironolactonum inn - tafla - 25 mg

Iceland - Tiếng Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

orion corporation - spironolactonum inn - tafla - 50 mg

Liên Minh Châu Âu - Tiếng Iceland - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolactone - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 5.

Iceland - Tiếng Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

orifarm healthcare a/s - spironolactonum inn - tafla - 50 mg

Iceland - Tiếng Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

orifarm healthcare a/s - spironolactonum inn - tafla - 25 mg

Liên Minh Châu Âu - Tiếng Iceland - EMA (European Medicines Agency)

ceva santé animale - benazepril hydrochloride, spironolactone - ÆÐakerfi - hundar - til meðferðar á hjartabilun vegna langvinna hrörnunarsjúkdóma í hundum (með þvagræsilyfjum eftir því sem við á).

Iceland - Tiếng Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

orion corporation - diltiazemum hýdróklóríð - forðatafla - 120 mg

Liên Minh Châu Âu - Tiếng Iceland - EMA (European Medicines Agency)

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - Æxlishemjandi lyf - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.